Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19212499 | 0.81 | ALDH1A1 (0.72) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL9223130 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL12200287 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL12200316 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL14852665 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL10247821 | 0.76 | ALDH1A1 (0.43) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL8080906 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL14047016 | 0.73 | ALDH1A1 (0.47) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL13236775 | 0.73 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1KMT2AHPGD | |
| SCHEMBL27030625 | 0.72 | ALDH1A1 (0.45) | ALDH1A1MAPTMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248987-A1 | Smooth muscle spasmolytic agents | BRIDGE PHARMA, INC. | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248987-A1 | Smooth muscle spasmolytic agents | MYLK, TNNC1, MYLK2 | ALDH1A1 230/4885MAPT 1988/4885MEN1 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.